Analyst Price Target is $15.40
▲ +589.04% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Alto Neuroscience in the last 3 months. The average price target is $15.40, with a high forecast of $43.00 and a low forecast of $4.00. The average price target represents a 589.04% upside from the last price of $2.24.
Current Consensus is
Moderate Buy
The current consensus among 7 investment analysts is to moderate buy stock in Alto Neuroscience. This rating has held steady since October 2024, when it changed from a Buy consensus rating.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.
Read More
